DK3906066T5 - Geneterapikonstruktioner til behandling af wilsons sygdom - Google Patents

Geneterapikonstruktioner til behandling af wilsons sygdom Download PDF

Info

Publication number
DK3906066T5
DK3906066T5 DK20704633.5T DK20704633T DK3906066T5 DK 3906066 T5 DK3906066 T5 DK 3906066T5 DK 20704633 T DK20704633 T DK 20704633T DK 3906066 T5 DK3906066 T5 DK 3906066T5
Authority
DK
Denmark
Prior art keywords
wilson
disease
treatment
gene therapy
therapy constructs
Prior art date
Application number
DK20704633.5T
Other languages
Danish (da)
English (en)
Other versions
DK3906066T3 (da
Inventor
Christine Livingston
Samuel Wadsworth
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Application granted granted Critical
Publication of DK3906066T3 publication Critical patent/DK3906066T3/da
Publication of DK3906066T5 publication Critical patent/DK3906066T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK20704633.5T 2019-01-04 2020-01-03 Geneterapikonstruktioner til behandling af wilsons sygdom DK3906066T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788324P 2019-01-04 2019-01-04
US201962834830P 2019-04-16 2019-04-16
PCT/US2020/012131 WO2020142653A1 (en) 2019-01-04 2020-01-03 Gene therapy constructs for treating wilson disease

Publications (2)

Publication Number Publication Date
DK3906066T3 DK3906066T3 (da) 2024-02-05
DK3906066T5 true DK3906066T5 (da) 2024-08-05

Family

ID=69528954

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20704633.5T DK3906066T5 (da) 2019-01-04 2020-01-03 Geneterapikonstruktioner til behandling af wilsons sygdom

Country Status (21)

Country Link
US (2) US12338450B2 (cg-RX-API-DMAC7.html)
EP (2) EP3906066B1 (cg-RX-API-DMAC7.html)
JP (2) JP7531495B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210112339A (cg-RX-API-DMAC7.html)
CN (1) CN113518628B (cg-RX-API-DMAC7.html)
AU (1) AU2020204679B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021013140A2 (cg-RX-API-DMAC7.html)
CO (1) CO2021010088A2 (cg-RX-API-DMAC7.html)
DK (1) DK3906066T5 (cg-RX-API-DMAC7.html)
ES (2) ES2970216T3 (cg-RX-API-DMAC7.html)
FI (1) FI3906066T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231750T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065782T2 (cg-RX-API-DMAC7.html)
IL (1) IL284554A (cg-RX-API-DMAC7.html)
MX (1) MX2021008135A (cg-RX-API-DMAC7.html)
PL (1) PL3906066T3 (cg-RX-API-DMAC7.html)
PT (1) PT3906066T (cg-RX-API-DMAC7.html)
SG (1) SG11202106855YA (cg-RX-API-DMAC7.html)
TW (1) TWI848038B (cg-RX-API-DMAC7.html)
WO (1) WO2020142653A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104515B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102863181B1 (ko) 2016-12-30 2025-09-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 윌슨병을 치료하기 위한 유전자 치료
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
KR20210112339A (ko) 2019-01-04 2021-09-14 울트라제닉스 파마수티컬 인코포레이티드 윌슨병을 치료하기 위한 유전자 요법 구축물
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
MX2021013913A (es) * 2019-05-14 2022-03-17 Univ Duke Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
JP2023542614A (ja) 2020-08-19 2023-10-11 サレプタ セラピューティクス, インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
CN115216481A (zh) * 2021-04-21 2022-10-21 四川至善唯新生物科技有限公司 一种表达量提高的截短型atp7b基因及其应用
CN113694218A (zh) * 2021-08-30 2021-11-26 昆明理工大学 一种atp7b基因p992l突变的基因修复治疗载体
AU2022407655A1 (en) * 2021-12-10 2024-06-20 Aavantibio, Inc. Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector
KR20240114769A (ko) * 2021-12-10 2024-07-24 애반티바이오, 인크. 증진된 발현을 위해 선택된 코작 서열을 포함하는 조성물
EP4677077A4 (en) * 2023-03-06 2026-07-29 Lingyi Biotech Co Ltd TRUNCATED ATP7B GENE AND ITS USAGE
JP2026508707A (ja) * 2023-03-22 2026-03-11 スカイライン、セラピューティクス、リミテッド ウィルソン病の遺伝子療法のための組換えaav
WO2025002226A1 (zh) * 2023-06-28 2025-01-02 迈威(上海)生物科技股份有限公司 编码atp7b的核酸、腺相关病毒载体及其在制备防治肝豆状核变性的药物中的应用
CN120882865A (zh) * 2023-07-28 2025-10-31 凌意(杭州)生物科技有限公司 用于治疗威尔逊病的多核苷酸

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
WO2003038049A2 (en) * 2001-10-29 2003-05-08 Renovis, Inc. Method for isolating cell-type specific mrnas
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DE10156121A1 (de) 2001-11-16 2003-05-28 Wolfgang Stremmel Somatische Gentherapie mit Vektoren, die einen verkürzten metallsensitiven Promotor besitzen, zur Behandlung des Morbus Wilson sowie anderer Erkrankungen, die mit Veränderungen im Metallstoffwechsel einhergehen, wie z.B. Alzheimer-Erkrankung
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法
WO2005012877A2 (en) 2003-08-01 2005-02-10 Dna Twopointo Inc. Systems and methods for antibody engineering
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
EP2242840B1 (en) 2008-01-29 2019-07-24 Applied Genetic Technologies Corporation Recombinant adeno-associated virus production using bhk cells in suspension
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
EP2529020B1 (en) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
WO2016049230A1 (en) 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
CN107208105A (zh) 2014-12-17 2017-09-26 基础应用医学研究基金会 用于治疗威尔森病的核酸构建体和基因治疗载体
US11118238B2 (en) 2014-12-17 2021-09-14 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson's disease and other conditions
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
US11015174B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
KR102863181B1 (ko) 2016-12-30 2025-09-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 윌슨병을 치료하기 위한 유전자 치료
CA3118936A1 (en) 2018-11-16 2020-05-22 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
KR20210112339A (ko) 2019-01-04 2021-09-14 울트라제닉스 파마수티컬 인코포레이티드 윌슨병을 치료하기 위한 유전자 요법 구축물
WO2023230466A1 (en) * 2022-05-23 2023-11-30 Lutsenka Svetlana Compositions and methods for treating wilson's disease

Also Published As

Publication number Publication date
EP4269579A2 (en) 2023-11-01
US20220090131A1 (en) 2022-03-24
PT3906066T (pt) 2024-02-06
EP4269579A3 (en) 2024-01-24
EP3906066B1 (en) 2023-11-01
EP4269579B1 (en) 2026-04-01
US20250333763A1 (en) 2025-10-30
CN113518628B (zh) 2025-04-29
ES3074005T3 (en) 2026-07-16
US12338450B2 (en) 2025-06-24
KR20210112339A (ko) 2021-09-14
JP2024054426A (ja) 2024-04-16
HUE065782T2 (hu) 2024-06-28
AU2020204679A1 (en) 2021-07-15
TW202043479A (zh) 2020-12-01
TWI848038B (zh) 2024-07-11
JP7746437B2 (ja) 2025-09-30
CA3124880A1 (en) 2020-07-09
BR112021013140A2 (pt) 2021-11-30
ZA202104515B (en) 2024-12-18
JP2022516283A (ja) 2022-02-25
CN113518628A (zh) 2021-10-19
FI3906066T3 (fi) 2024-01-30
HRP20231750T1 (hr) 2024-05-24
MX2021008135A (es) 2021-08-11
IL284554A (en) 2021-08-31
CO2021010088A2 (es) 2021-09-20
PL3906066T3 (pl) 2024-09-02
WO2020142653A1 (en) 2020-07-09
AU2020204679B2 (en) 2026-01-08
DK3906066T3 (da) 2024-02-05
SG11202106855YA (en) 2021-07-29
JP7531495B2 (ja) 2024-08-09
ES2970216T3 (es) 2024-05-27
EP3906066A1 (en) 2021-11-10
EP4269579C0 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
DK3906066T3 (da) Geneterapikonstruktioner til behandling af wilsons sygdom
IL279918A (en) Gene therapy vectors for treatment of danon disease
EP3562514A4 (en) GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
EP3813634A4 (en) ARTICULATING MEDICAL INSTRUMENTS
EP3873335A4 (en) CHARACTERIZATION OF THERAPEUTIC EFFECTIVENESS OF NEUROSTIMULATION
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
IL285238A (en) Gene therapy vectors for treatment of danon disease
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
EP3880809A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF WILSON'S DISEASE
EP3963063A4 (en) COMPOSITIONS FOR THE TREATMENT OF POMPE'S DISEASE
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
DK3233129T3 (da) Nukleinsyrekonstrukter og genterapivektorer til anvendelse i behandlingen af wilsons sygdom og andre lidelser
EP3802539C0 (en) NOVEL TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
IL284414A (en) Methods and compositions for the treatment of fabry disease
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
IL282827A (en) Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
EP4045036C0 (en) HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 ASSOCIATED DISEASES
MA56047A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
IL281244A (en) Combination therapy for the treatment of liver disease
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP4009948A4 (en) USE OF TGF-ALPHA POLYPEPTIDES OR ANTI-TGF-ALPHA ANTIBODIES FOR TREATING DISEASES AND DISORDERS